Bieche We, Parfait B, Tozlu S, Lidereau Roentgen, Vidaud Yards: Quantitation regarding androgen receptor gene term within the sporadic nipple tumors because of the real-go out RT-PCR: evidence that MYC was a keen AR-controlled gene. Carcinogenesis. 2001, twenty two (9): 1521-1526. /carcin/twenty two.9.1521.
Bratthauer GL, Lininger RA, Son YG, Tavassoli FA: Androgen and you will estrogen receptor mRNA status within the apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical studies out of apocrine nipple sores. Uniform more than-term away from androgen receptor accompanied by losing the hormone estrogen and progesterone receptors during the apocrine metaplasia and you will apocrine carcinoma for the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Am J Clin Pathol
Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S: Androgen receptors during the operable cancer of the breast: regards to other steroid hormones receptors, correlations in order to prognostic points and you may predictive worth for aftereffect of additive tamoxifen medication. Eur J Surg Oncol. 1992, 18 (2): 112-118.
Bayer-Gather IB, Smoller B: Androgen receptors: an effective marker to boost sensitivity to have determining cancer of the breast from inside the skin metastasis regarding unknown pri, thirteen (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic passion and you will medical effects. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales Good, Skoog L, Chuan YC, Nordstedt Grams, Pousette An effective: Regulation regarding matrix metalloproteinase thirteen expression by the androgen inside the prostate disease. Oncol Agent. 2004, eleven (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.
Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Research of one’s prognostic requirement for androgen receptor term into the metastatic cancer of the breast. Virchows Arch. 2006, 449 (1): 24-31. /s00428-006-0213-6.
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari Yards, Gilks CB: Assessment out-of interlaboratory adaptation regarding immunohistochemical commitment from estrogen receptor updates having fun with a breast cancer structure microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Examination of matrix metalloproteinases as well as their inhibitors for the breast cancer. Br J Disease. 2007, 96 (6): 903-911. /sj.bjc.6603666.
Narita D, Raica Yards, Suciu C, Cimpean An excellent, Anghel A good: Immunohistochemical term out of androgen receptor and prostate-particular antigen inside the breast cancer. Folia Histochem Cytobiol. 2006, forty-two (3): 165-172.
Egeblad M, Werb Z: The newest qualities into the matrix metalloproteinases in cancer tumors evolution. Nat Rev Cancer. 2002, 2 (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–towards fundamental stage of cancers?. Cancer tumors Cell. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente Yards, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Age, Martinez Air cooling: The fresh matrix metalloproteinase-9 regulates this new insulin-including progress basis-brought about autocrine response in DU-145 carcinoma muscle. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Elizabeth, Matrisian LM, Mareel Meters: Discharge of an attack promoter Age-cadherin fragment by the matrilysin and stromelysin-1. J Cell Sci. 2001, 114 (Pt step 1): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] term picks getting structure with reduced susceptibility in order to apoptosis. Neoplasia. 2001, 3 (6): 459-468. /sj.neo.7900190.
CO;2-H
Stetler-Stevenson WG: Matrix metalloproteinases inside the angiogenesis: a relocation target having therapeutic input. J Clin Invest. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius Los angeles, Nehring LC, Harding Elizabeth, Bolanowski Yards, Welgus HG, Kobayashi DK, Enter RA, Shapiro SD: Matrix metalloproteinases build angiostatin: outcomes into the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y datingranking.net/tr/quiver-inceleme, Goldberg ID, Shi YE: Cutting-edge positions off cells inhibitors out of metalloproteinases into the cancers. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.